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INTRODUCTION
After basal and squamous cell skin cancers, prostate
cancer is the most frequent cancer in men in the United
States, with 186,320 men estimated to be diagnosed
with the disease and 28,660 expected to die from it in
2008 1. Approximately 90% of hematogenous
metastases in prostate cancer patients occur in bone 2,
making skeletal complications the leading cause of
morbidity and mortality in these patients.
Although skeletal metastases from prostate can-
cer are usually considered osteoblastic by radiologic
analysis, histologic and biochemical studies suggest that
osteolytic and osteoblastic responses are sequentially
linked 3–5. A vicious cycle in which prostate cancer
cells secrete factors that stimulate bone matrix turno-
ver, which in turn releases growth factors that enhance
tumour proliferation, has been proposed 6. In the nor-
mal bone microenvironment, endosteal cells
(osteoblasts, osteoclasts) and bone marrow cells
(fibroblasts, pre-osteoblasts, pre-osteoclasts, lymphoid
and myeloid cells, endothelial cells, hematopoietic and
mesenchymal stem cells) communicate with each other
in a homeostatic process that involves transmission of
various biologic signals. However, this delicate equi-
librium is perturbed when prostate cancer cells colo-
nize the bone, leading to an alteration of the physiologic
balance between bone formation and bone resorption,
and to a hospitable environment for expansion of the
metastases 7.
A role for matrix metalloproteinases (MMPs) in bone
metastasis has long been suspected. Because MMPs
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contribute to the process of normal bone remodelling,
and because enhanced turnover of bone matrix occurs
when tumour cells metastasize to bone, a role can be
predicted for these enzymes in metastasis-associated
bone modification.
MMPs AT A GLANCE
The MMP family of Zn2+-dependent endopeptidases
comprises at least 24 members, which have the com-
bined capacity to degrade virtually all the structural
components of extracellular matrix [ECM (for review
see 8,9)]. Most MMPs are secreted, although 6 of them
are membrane-tethered (MT) proteins that have the
ability to mediate proteolytic events at both the cell
surface and in the immediate pericellular milieu. The
MMPs consist of an N-terminal signal sequence, a
propeptide domain, a catalytic domain, and a C-termi-
nal domain known as the hemopexin-like domain. In
the case of the MT-MMPs, a C-terminal transmembrane
domain or a glycosylphosphatidylinisotol link domain
is added.
All MMPs are synthesized as inactive zymogens
and are maintained as such by coordination of a cysteine
residue within the propeptide domain, with a Zn2+ ion
present in the catalytic domain, which prevents bind-
ing and cleavage of the substrate. The dissociation of
cysteine from the Zn2+ atom, known as “cysteine
switch,” is a complex process, the details of which
have emerged only recently 10. The activity of MMPs
is specifically inhibited by tissue inhibitors of MMPs
(TIMPs: TIMP-1, TIMP-2, TIMP-3, and TIMP-4), which
usually bind to the active species, inhibiting catalysis.
In some MMPs, the TIMPs can bind to the zymogens.
For a long time, the significance of the binding of
certain TIMPs to the latent form of some MMPs was
unclear. It is now known that, for example, low con-
centrations of TIMP-2 can promote activation of pro-
MMP-2 through a mechanism in which TIMP-2 acts as
a linker between the pro-MMP-2 zymogen and MT1-
MMP at the cell surface. In this way, the propeptide of
the pro-MMP-2 present in this ternary complex formed
on the cell surface is cleaved by an adjacent active
MT1-MMP. Conversely, high levels of TIMP-2 relativeBONFIL et al.
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to MT1-MMP would inhibit activation by blocking all
free MT1-MMP molecules.
Initially, MMPs were recognized as proteinases
exclusively committed to ECM remodelling during in-
vasive, angiogenic, and metastatic processes. They are
now known to have additional roles, such as activation
of growth factors, cleavage of cell surface receptors,
release of angiogenic factors, release of apoptotic
ligands, and generation of angiostatic molecules, to
mention just a few. These multiple roles demonstrate
the complexity and multiplicity of the substrates of
MMPs and their ample range of biologic activity in nor-
mal and pathologic conditions alike.
MMPs AND PROSTATE CANCER BONE
METASTASES
Cancer cells that disseminate to bone alter the normal
skeletal remodelling process, upsetting the balance
between bone formation and bone resorption. Because
MMPs are involved in the physiologic turnover of ECM
and in bone remodelling, a contribution of MMPs to pros-
tate cancer bone metastasis seems to be reasonable.
In fact, the participation of MMPs in the pathogenesis
of osteolytic prostate cancer bone metastasis was con-
firmed by several experimental studies.
More than 10 years ago, it was shown that the com-
bined administration of alendronate (a bisphosphonate
compound) and of paclitaxel inhibits bone metastases
produced in severe combined immunodeficient (SCID)
mice by intravenous inoculation of human PC-3 ML
cancer cells. This effect was mainly the result of a
complete abrogation of the production and secretion of
MMPs 11. In vitro, it was found that PC-3 cells produce
and secrete MMPs when placed on bone surfaces 12,
and that MMP2 and MMP9 are among a set of genes
altered when prostate cancer cells and bone marrow
stromal cells interact 13. Those findings were further
supported by studies in prostate cancer patients with
skeletal metastases who had elevated serum levels of
MMP-2 and MMP-9 14,15.
Using the SCID-hu model for bone metastasis, in
which human prostate cancer cells are grown in human
bone xenografts in SCID mice 16, we confirmed high
expression of MMP-2 and MMP-9 in cancer cells and in
neighbouring bone stromal cells. Those data were con-
sistent with our observations in bone biopsy specimens
obtained from prostate cancer patients 17. Moreover,
systemic administration to the mice of the broad-spec-
trum MMP inhibitor BB-94 (batimastat) inhibited the
proliferation of prostate tumour cells growing within the
human bone implants. That inhibition was accompanied
by reduced degradation of bone marrow trabeculae and
decreased osteoclast recruitment 17.
Recently, we showed an upregulation of net MMP-
9 activity shortly after establishment of PC-3 cells in
human bone xenografts—an increase that coincided
with a wave of osteoclast recruitment and vigorous bone
degradation 18. Experimentally, the activation of MMP-9
that occurs during prostate cancer–bone interaction is
species-specific, because active MMP-9 was found
when human prostate cancer cells grew within hu-
man bone tissue, but not when they grew within mouse
bones 19.
Tumour-associated osteoclasts are known initially
to dissolve the mineralized bone matrix by acid secre-
tion and then to disrupt the exposed non-mineralized
ECM by using proteases. Although MMP-9 does not de-
grade type I collagen, the most abundant organic com-
ponent in bone, we found that the protease is expressed
mainly by osteoclasts. That finding suggests that ac-
tive MMP-9 induced by prostate cancer–bone interac-
tion most likely contributes to osteolysis by indirect
mechanisms. For instance, MMP-9 may cause the re-
lease of ECM-bound vascular endothelial growth fac-
tor into a soluble and bioactive form 20, thereby
favouring the angiogenesis of intraosseous prostate tu-
mours and the subsequent growth of those tumours.
That effect ultimately stimulates new osteoclastic ac-
tivity necessary to gain more space for expansion of
the tumours.
The foregoing hypothesis was confirmed by experi-
mental therapy with SB-3CT, a novel mechanism-based
MMP inhibitor with high selectivity for MMP-9 21,22.
This inhibitor is primed, in a chemical step, for potent
inhibition of gelatinases once bound to the active sites
of these enzymes. Treatment with SB-3CT of SCID
mice bearing prostate cancer bone tumours resulted in
significant inhibition of angiogenesis and intraosseous
tumour growth, together with reduction in osteolysis 23.
Those results indicate an important contribution of
MMP-9 to neovascularization of expanding bone me-
tastases and to subsequent bone degradation. Moreover,
pro-MMP-9 has been shown to play a crucial role in os-
teoclast recruitment 24. The existence of abnormalities
in developmental angiogenesis and ossification in mice
with null mutation in MMP9 24,25 further supports the
importance of MMP-9 not only in normal but in pathologic
processes occurring in the skeleton.
Membrane-tethered 1 MMP knockout mice also
present severe skeletal abnormalities, mostly as a re-
sult of their incapacity to degrade crosslinked fibril-
lar type I collagen prevalent in the bone matrix 26. In
prostate cancer, MT1-MMP expression correlates with
a more aggressive behaviour and has been shown to
promote invasion and metastasis 27–29. Immunohis-
tochemical studies of primary prostate adenocarci-
nomas revealed a heterogeneous pattern, with some
malignant glands positive and others negative for MT1-
MMP 30. That finding, together with a uniform and
strong MT1-MMP expression observed in all cases of
prostate cancer bone metastases analyzed 31, suggests
the existence of a selective process in which MT1-
MMP–expressing prostate cancer cells may have more
tendency to metastasize to skeleton. Alternatively, the
bone microenvironment might induce the expression
of MT1-MMP in prostate cancer cells after their arrival
in the marrow.MMPS AND BONE METASTASIS IN PROSTATE CANCER
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We conducted a series of studies to assess the con-
tribution of prostate cancer cell–derived MT1-MMP to
bone metastasis. We overexpressed MT1-MMP in
LNCaP human prostate cancer cells (which have base-
line non-detectable expression of the protease), while
its expression was attenuated in DU145 cells (which
have baseline high MT1-MMP expression) using small
interfering RNA. We showed that intratibial injection
of those cells resulted in completely opposite pheno-
types in terms of intraosseous tumour growth and bone
response. Compared with controls, tibiae injected with
LNCaP cells overexpressing MT1-MMP showed in-
creased osteolysis (as demonstrated by radiography and
histomorphometry) and enhanced intraosseous tumour
growth. In contrast, MT1-MMP downregulation in high-
expressing MT1-MMP DU145 prostate cancer cells led
to diminished intraosseous tumour growth and a mixed
bone reaction, in which osteosclerotic responses pre-
dominated 31. We further showed that MT1-MMP
upregulation in cancer cells resulted in the release of
one or more factors that promoted osteoclast differen-
tiation in vitro. That effect was abrogated by
pharmacologic inhibition of MT1-MMP activity and by
osteoprotegerin, a soluble decoy receptor of the
osteoclastogenic receptor activator of nuclear factor
κB ligand (RANKL). Our results strongly suggest the
possibility that prostate cancer–associated MT1-MMP
promotes an osteolytic response by shedding mem-
brane-bound RANKL (mRANKL) from the cancer cell
surface. Recently, MMP-7, produced mainly by
osteoclasts at the prostate tumour–bone interface, has
also been reported as a RANKL “sheddase,” promoting
osteolysis 32. Together, these data suggest that specific
inhibition of certain MMPs in prostate cancer bone
metastasis may be therapeutically beneficial.
NEW THERAPEUTIC CHALLENGES
Much of the initial excitement associated with the use
of broad-spectrum MMP inhibitors in animal tumour
models has been mitigated by a lack of therapeutic
efficacy and undesired side effects observed in clini-
cal trials with cancer patients 33–35. Some of the po-
tential reasons for the failure of these agents include
￿ testing of patients with advanced high-volume dis-
ease refractory to other treatments;
￿ use of broad-spectrum inhibitors of MMPs with
unspecific and reversible effects;
￿ unknown repertoire of proteases expressed by the
patients’ tumours (protease “degradome” 36) be-
fore and during treatment;
￿ unintended inhibition of MMPs with important
physiologic roles (anti-targets), probably resulting
in neutralization of the effects of the inhibitors on
actual MMP “targets” that truly contribute to dis-
ease 37;
￿ lack of studies to monitor MMP inhibition during
treatment; and
￿ unknown effective doses of MMP inhibitors and
diminished therapeutic index because of forced
dose reduction to tolerable levels.
The first drugs developed for MMP inhibition were
peptidomimetic hydroxamate compounds with potent
inhibitory effects, but no selectivity (for example,
batimastat). The second-generation MMP inhibitors
exhibited some marginal selectivity (for example,
prinomastat). Because those compounds failed in clini-
cal trials, a third generation of selective MMP inhibi-
tors is now being developed and considered for cancer
therapy 38,39, aiming to obtain the maximal effect on
the disease in which the MMP target is involved with
minimal adverse reactions. These selective inhibitors
are hoped to have a ratio of at least 1000 between the
Ki (the dissociation constant for binding of inhibitor) val-
ues for MMP anti-targets and those for MMP targets 38,39.
These prospects should be explored and might prove
efficacious, but even selectivity by a factor of 1000
might not solve the clinical riddle of compounds that
serve as linear competitive inhibitors.
For example, potent linear competitive inhibition
of target MMPs at low nanomolar or picomolar levels
in vitro, despite the “factor of 1000” selectivity, might
not prove selective in vivo because a low micromolar
or high nanomolar level of activity against the anti-
target MMPs will still foster in vivo consequences. The
challenge is not necessarily an issue of affinity for the
target, but rather of the mechanism for discrimination
other than mere recognition events between the drug
and the target. In that vein, the mechanism-based
gelatinase inhibitor SB-3CT and its new structural vari-
ants stand out. This inhibitor class takes advantage of
the active site of the enzyme to undergo a specific
chemical transformation facilitated by the target en-
zyme itself. Whether a given MMP might be able to
perform this reaction, or whether it might not, a proc-
ess that leads to potent enzyme inhibition is at the root
of its ability to serve as a selective MMP inhibitor to
the given target. The concepts pertinent to inhibition of
MMP have been discussed in a recent review 40.
In the particular case of prostate cancer patients,
no clinical trials have been performed to evaluate the
therapeutic efficacy of MMP inhibitors on bone metas-
tasis. We believe that the knowledge obtained in re-
cent years using animal models has provided validated
MMP targets that, together with the development of third-
generation MMP inhibitors, would justify use of those
inhibitors in the treatment of prostate cancer patients
with skeletal metastasis. For instance, prostate cancer
patients with locally advanced disease who have a high
probability of developing bone metastasis and no cur-
rent prospect of curative treatment could benefit from
therapy with novel MMP inhibitors.
For successful treatment, it is crucial that the pro-
tease degradome for tumours in each patient be as-
sessed and that inhibition of the MMP being targeted be
confirmed by appropriate methods during treatment.BONFIL et al.
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Alternatively, combination therapy using inhibitors for
MMP targets and agents that can block osteoclastic
action (such as bisphosphonates or anti-RANKL drugs)
could reasonably be employed in clinical trials involving
prostate cancer patients with potential to develop bone
metastases. The experimental evidence described
herein showing a key role for MMPs in bone metastasis
suggests that targeting those MMPs could have thera-
peutic value. New approaches must be explored, es-
pecially given that current approaches for treating bone
metastasis in prostate cancer patients are still limited
and only palliative.
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